Scotia Capital’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Scotia Capital’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,000	Closed	-$6K	–	777
2019 Q4	$6K	Hold	1,000	–	–	﹤0.01%	735
2019 Q3	$8K	Hold	1,000	–	–	﹤0.01%	723
2019 Q2	$7K	Hold	1,000	–	–	﹤0.01%	722
2019 Q1	$8K	Hold	1,000	–	–	﹤0.01%	694
2018 Q4	$16K	Hold	1,000	–	–	﹤0.01%	649
2018 Q3	$33K	Hold	1,000	–	–	﹤0.01%	707
2018 Q2	$28K	Hold	1,000	–	–	﹤0.01%	659
2018 Q1	$29K	Hold	1,000	–	–	﹤0.01%	690
2017 Q4	$28K	Buy	+1,000	New	+$31K	﹤0.01%	703

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

XSC

X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Scotia Capital's AVEO Position: Q1 2020 in Review

Scotia Capital sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2020, closing a stake of 1,000 shares — an estimated $6K sold.

Scotia Capital first reported a position in AVEO in Q4 2017 and held it in 9 quarters. The position peaked at $33K in Q3 2018. 35 funds tracked by Wall St. Rank hold AVEO as of Q1 2020.

Scotia Capital reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Scotia Capital sold 1,000 AVEO Pharmaceuticals, Inc. shares in Q1 2020, an estimated $6K.
Scotia Capital first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2017 and held it in 9 quarters.
Scotia Capital's AVEO Pharmaceuticals, Inc. position peaked at $33K in Q3 2018.
35 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2020.

Based on Scotia Capital's 13F filing for Q1 2020, filed 15 May 2020.